North America Nuclear Medicine Market - Strategic Insights and Forecasts (2026-2031)

The North American Nuclear Medicine Market is projected to surge at a CAGR of 14.8%, reaching USD 16.5 billion in 2031 from USD 8.28 billion in 2026.

The North America nuclear medicine market is undergoing significant transformation driven by the paradigm shift toward precision oncology, the expansion of theranostics, and the growing integration of molecular imaging into routine clinical practice. The market's evolution is characterized by the recognition that nuclear medicine technologies provide functional information that conventional anatomical imaging often cannot deliver, making them essential for treatment planning, disease staging, therapy monitoring, and recurrence detection across multiple cancer indications. The convergence of radiopharmaceutical innovation, advanced imaging systems, and targeted therapy platforms is enabling more precise diagnosis and personalized treatment strategies. Healthcare providers are adopting PET and SPECT procedures as they become integrated into treatment planning across prostate cancer, neuroendocrine tumors, lymphoma, and other oncology applications. The commercial success of PSMA-targeted imaging products demonstrates how precision diagnostics are becoming embedded within treatment pathways. The market is witnessing significant investment in isotope production infrastructure, radiopharmaceutical manufacturing, and distribution networks, positioning nuclear medicine as a cornerstone of modern precision medicine.

Market Drivers

• The expansion of precision oncology diagnostics represents the primary driver for the North America nuclear medicine market. Prostate cancer, neuroendocrine tumors, lymphoma, and other oncology applications are increasing the use of PET imaging agents. The commercial success of PSMA-targeted imaging products demonstrates how precision diagnostics are becoming embedded within treatment pathways. Recent FDA approvals and pipeline expansion activities indicate continued investment in oncology-focused radiopharmaceuticals. Suppliers are responding through investments in radiopharmaceutical manufacturing, isotope supply agreements, and expanded distribution capabilities. Higher utilization rates improve economics for hospitals and diagnostic providers while increasing recurring demand for imaging agents, resulting in sustained growth in nuclear medicine utilization. The growth of theranostics and targeted radiopharmaceutical therapies is further accelerating market expansion through integrated diagnostic and therapeutic platforms. Theranostics combines diagnostic imaging and targeted radionuclide therapy using related molecular targets. This approach is expanding beyond prostate cancer into additional oncology indications. Industry organizations identify theranostics as one of the most important areas of future nuclear medicine development because it links diagnosis, treatment selection, and therapy monitoring within a single clinical pathway. The commercial impact extends beyond imaging procedures, with suppliers generating revenue from diagnostic agents, therapeutic isotopes, manufacturing services, and clinical support programs. The increasing burden of cancer and neurological disorders is driving demand for molecular imaging to support earlier diagnosis and more accurate treatment decisions. Healthcare systems are expanding the use of molecular imaging to support earlier diagnosis and more accurate treatment decisions. PET imaging is increasingly used in neurodegenerative disease assessment and oncology management. Nuclear medicine provides functional information that complements CT and MRI. Investments in isotope production infrastructure are strengthening supply security and supporting commercialization of emerging radiopharmaceutical products. Supply security has become a strategic concern across North America.

Market Restraints

• Dependence on international isotope supply chains creates vulnerability to disruptions. Many critical medical isotopes used in North America originate outside the United States. Commercial molybdenum-99, the precursor for technetium-99m, remains heavily dependent on international supply networks. Short half-life and complex distribution requirements increase logistics costs and limit geographic flexibility. Many isotopes decay rapidly and require highly coordinated production, processing, transportation, and administration schedules. Regulatory approval and manufacturing compliance burdens affect commercialization schedules. Radiopharmaceutical development requires compliance with pharmaceutical, radiation safety, transportation, and manufacturing regulations. Capacity constraints in high-growth PET applications affect scheduling, equipment replacement decisions, and radiopharmaceutical demand planning.

Technology and Product Insights

• The technology landscape is characterized by the growing importance of PET imaging, theranostic platforms, and radiopharmaceutical innovation. The PET segment represents the most commercially important application category because demand is supported by oncology imaging, neurological assessment, cardiovascular diagnostics, and expanding theranostic applications. PET imaging offers higher sensitivity and quantitative capabilities than many conventional nuclear imaging procedures, making it increasingly important in precision medicine. Hospitals and advanced diagnostic centers are the primary purchasers, with buying criteria emphasizing tracer availability, reimbursement support, image quality, workflow integration, and access to emerging clinical applications. The increasing use of PSMA-targeted imaging for prostate cancer and specialized tracers for neurodegenerative diseases has strengthened the segment's revenue profile. The segment analysis reveals that competitive activity increasingly centers on radiopharmaceutical portfolios rather than imaging hardware alone. Suppliers that combine tracer development, isotope access, regulatory expertise, and distribution infrastructure are better positioned to capture value. The United States accounts for the largest share of regional demand due to its extensive hospital network, advanced cancer care infrastructure, and strong radiopharmaceutical development activity, with approximately 20 million nuclear medicine procedures performed annually. Canada occupies a strategically important position within the isotope supply chain, with reactor facilities, cyclotron networks, isotope processors, and research institutions contributing to domestic and international supply. The integration of theranostic platforms is becoming increasingly important as theranostics links diagnosis, treatment selection, and therapy monitoring within a single clinical pathway.

Competitive and Strategic Outlook

• The competitive landscape exhibits characteristics of a technology-driven and supply-chain-intensive industry where competitive advantage depends on isotope access, regulatory expertise, radiopharmaceutical development capabilities, distribution infrastructure, and clinical adoption support. Major participants include Bracco, Cambridge Isotope Laboratories, Cardinal Health, FUJIFILM Holdings, GE HealthCare, Nordion, Taiyo Nippon Sanso Corporation, Lantheus Medical Imaging, Philips, and Digirad Corporation. Competition increasingly favors companies capable of integrating radiopharmaceutical development with manufacturing and distribution. Lantheus has expanded its precision diagnostics portfolio and continues to invest in oncology imaging products. Cardinal Health benefits from its extensive nuclear pharmacy network, while GE HealthCare and Philips leverage installed imaging equipment bases and hospital relationships. Barriers to entry remain high because participants must secure isotope supply, maintain regulatory compliance, establish specialized logistics capabilities, and build clinical acceptance among physicians and healthcare systems. Recent key developments include the FDA approving Lantheus' Pylarify TruVu formulation for prostate cancer imaging, increasing production efficiency and potentially expanding access to PSMA PET imaging across underserved regions. Siemens Healthineers integrated PETNET Solutions and Advanced Accelerator Applications under its Radiopharma segment, unifying one of North America's largest radiopharmaceutical distribution networks. Iotron Medical joined the Canadian Nuclear Isotope Council to support commercialization of copper-67 isotope production. Lantheus acquired Evergreen Theragnostics, gaining OCTEVY, a late-stage PET imaging agent for neuroendocrine tumors, alongside radioligand therapy manufacturing infrastructure. Telix finalized its acquisition of RLS (USA), adding a nationwide radiopharmacy network with more than 30 locations.

Short Conclusion

• The North America nuclear medicine market is positioned for sustained growth driven by the convergence of precision oncology, theranostic innovation, and isotope production investment. The transition from diagnostic imaging toward integrated precision therapy platforms represents a fundamental shift in nuclear medicine. While challenges related to isotope supply dependence, regulatory complexity, and distribution constraints persist, strategic investments in radiopharmaceutical development, manufacturing infrastructure, and distribution networks are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with nuclear medicine evolving into a cornerstone of precision medicine, supporting earlier diagnosis, targeted therapy, and improved patient outcomes across North American healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments